Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study - United States, August 19, 2022-March 31, 2023

• Type of Material: Article
• Authors: Alexandra F. Dalton, Centers for Disease Control and Prevention; Alpha Oumar Diallo, Centers for Disease Control and Prevention; Anna N. Chard, Centers for Disease Control and Prevention; Danielle L. Moulia, Centers for Disease Control and Prevention; Nicholas P. Deputy, Centers for Disease Control and Prevention; Amy Fothergill, Centers for Disease Control and Prevention; Ian Kracalik, Centers for Disease Control and Prevention; Christopher W. Wegner, California Emerging Infections Program; Monica Farley, Emory University
• Language: English
• Date: 2023-05-19
• Publisher: CENTERS DISEASE CONTROL & PREVENTION
• Publication Version: Final Published Version
• Copyright Statement: All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.
• Final Published Version (URL): http://dx.doi.org/10.15585/mmwr.mm7220a3
• Title of Journal or Parent Work: MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
• Volume: 72
• Issue: 20
• Start Page: 553
• End Page: 558
• Keywords: RISK; Science & Technology; Public, Environmental & Occupational Health; Life Sciences & Biomedicine; RECEIPT
• Research Categories: Health Sciences, Public Health; Biology, Virology

Abstract

As of March 31, 2023, more than 30,000 monkeypox (mpox) cases had been reported in the United States in an outbreak that has disproportionately affected gay, bisexual, and other men who have sex with men (MSM) and transgender persons (1). JYNNEOS vaccine (Modified Vaccinia Ankara vaccine, Bavarian Nordic) was approved by the Food and Drug Administration (FDA) in 2019 for the prevention of smallpox and mpox via subcutaneous injection as a 2-dose series (0.5 mL per dose, administered 4 weeks apart) (2). To expand vaccine access, an Emergency Use Authorization was issued by FDA on August 9, 2022, for dose-sparing intradermal injection of JYNNEOS as a 2-dose series (0.1 mL per dose, administered 4 weeks apart) (3). Vaccination was available to persons with known or presumed exposure to a person with mpox (postexposure prophylaxis [PEP]), as well as persons at increased risk for mpox or who might benefit from vaccination (preexposure mpox prophylaxis [PrEP]) (4). Because information on JYNNEOS vaccine effectiveness (VE) is limited, a matched case-control study was conducted in 12 U.S. jurisdictions,† including nine Emerging Infections Program sites and three Epidemiology and Laboratory Capacity sites,§ to evaluate VE against mpox among MSM and transgender adults aged 18-49 years. During August 19, 2022-March 31, 2023, a total of 309 case-patients were matched to 608 control patients. Adjusted VE was 75.2% (95% CI = 61.2% to 84.2%) for partial vaccination (1 dose) and 85.9% (95% CI = 73.8% to 92.4%) for full vaccination (2 doses). Adjusted VE for full vaccination by subcutaneous, intradermal, and heterologous routes of administration was 88.9% (95% CI = 56.0% to 97.2%), 80.3% (95% CI = 22.9% to 95.0%), and 86.9% (95% CI = 69.1% to 94.5%), respectively. Adjusted VE for full vaccination among immunocompromised participants was 70.2% (95% CI = -37.9% to 93.6%) and among immunocompetent participants was 87.8% (95% CI = 57.5% to 96.5%). JYNNEOS is effective at reducing the risk for mpox. Because duration of protection of 1 versus 2 doses remains unknown, persons at increased risk for mpox exposure should receive the 2-dose series as recommended by the Advisory Committee on Immunization Practices (ACIP),¶ regardless of administration route or immunocompromise status.